TY - JOUR
T1 - Effects of psychosocial factors on monitoring treatment effect in newly diagnosed rheumatoid arthritis patients over time
T2 - response data from the tREACH study
AU - Kuijper, T. M.
AU - Luime, J. J.
AU - Xiong, H.
AU - de Jong, P. H. P.
AU - van der Lubbe, P. A. H. M.
AU - van Zeben, D.
AU - Tchetverikov, I.
AU - Hazes, J. M. W.
AU - Weel, A. E. A. M.
PY - 2018
Y1 - 2018
N2 - Objectives: To investigate whether, apart from effects of patient- and disease-related factors, psychosocial factors have additional effects on disease activity; and which factors are most influential during the first year of treatment in early rheumatoid arthritis (RA).Method: The study assessed 15month follow-up data from patients in tREACH, a randomized clinical trial comparing initial triple disease-modifying anti-rheumatic drug therapy to methotrexate monotherapy, with glucocorticoid bridging in both groups. Patients were evaluated every 3months and treated to target. Associations between Disease Activity Score (DAS) at 3, 9, and 15months and psychosocial factors (anxiety, depression, fatigue, and coping with pain) at the previous visit were assessed by multivariable linear regression correcting for demographic, clinical, and treatment-related factors.Results: At 3, 9, and 15months of follow-up, 265, 251, and 162 patients, respectively, were available for analysis. Baseline anxiety and coping with pain were associated with DAS at 3months; coping with pain at 6months was associated with DAS at 9months, and fatigue at 12months with DAS at 15months. Psychosocial factors were moderately correlated. Effects on DAS were mainly due to tender joint count and global health.Conclusion: Psychosocial factors have additional effects on DAS throughout the first year of treatment in early RA. A change was observed from anxiety and coping with pain at baseline being associated with subsequent DAS towards fatigue being associated with subsequent DAS at 12months. Owing to the explorative nature of this study, more research is needed to confirm this pattern.
AB - Objectives: To investigate whether, apart from effects of patient- and disease-related factors, psychosocial factors have additional effects on disease activity; and which factors are most influential during the first year of treatment in early rheumatoid arthritis (RA).Method: The study assessed 15month follow-up data from patients in tREACH, a randomized clinical trial comparing initial triple disease-modifying anti-rheumatic drug therapy to methotrexate monotherapy, with glucocorticoid bridging in both groups. Patients were evaluated every 3months and treated to target. Associations between Disease Activity Score (DAS) at 3, 9, and 15months and psychosocial factors (anxiety, depression, fatigue, and coping with pain) at the previous visit were assessed by multivariable linear regression correcting for demographic, clinical, and treatment-related factors.Results: At 3, 9, and 15months of follow-up, 265, 251, and 162 patients, respectively, were available for analysis. Baseline anxiety and coping with pain were associated with DAS at 3months; coping with pain at 6months was associated with DAS at 9months, and fatigue at 12months with DAS at 15months. Psychosocial factors were moderately correlated. Effects on DAS were mainly due to tender joint count and global health.Conclusion: Psychosocial factors have additional effects on DAS throughout the first year of treatment in early RA. A change was observed from anxiety and coping with pain at baseline being associated with subsequent DAS towards fatigue being associated with subsequent DAS at 12months. Owing to the explorative nature of this study, more research is needed to confirm this pattern.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000432559500002&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1080/03009742.2017.1349176
DO - 10.1080/03009742.2017.1349176
M3 - Article
C2 - 28967272
SN - 0300-9742
VL - 47
SP - 178
EP - 184
JO - Scandinavian Journal of Rheumatology
JF - Scandinavian Journal of Rheumatology
IS - 3
ER -